Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

@article{Farkouh2004ComparisonOL,
  title={Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial},
  author={Michael E. Farkouh and Howard Kirshner and Robert A. Harrington and Sean D. Ruland and on behalf of the Target Study Group},
  journal={The Lancet},
  year={2004},
  volume={364},
  pages={675-684}
}
BACKGROUND The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen. METHODS 18325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 190 CITATIONS, ESTIMATED 42% COVERAGE

Cardiovascular adverse effects of anti-inflammatory drugs.

  • Anti-inflammatory & anti-allergy agents in medicinal chemistry
  • 2013
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

  • Naunyn-Schmiedeberg's Archives of Pharmacology
  • 2006
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Ibuprofen: pharmacology, efficacy and safety

  • Inflammopharmacology
  • 2009
VIEW 8 EXCERPTS
CITES RESULTS, BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2004
2019

CITATION STATISTICS

  • 16 Highly Influenced Citations